A detailed history of Legal & General Group PLC transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 27,155 shares of TARS stock, worth $1.22 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27,155
Previous 27,155 -0.0%
Holding current value
$1.22 Million
Previous $893,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$21.54 - $34.6 $2,003 - $3,217
93 Added 0.34%
27,155 $893,000
Q2 2024

Aug 14, 2024

BUY
$25.17 - $38.73 $106,494 - $163,866
4,231 Added 18.53%
27,062 $735,000
Q4 2023

Feb 15, 2024

BUY
$12.98 - $20.73 $29,581 - $47,243
2,279 Added 11.09%
22,831 $462,000
Q3 2023

Nov 14, 2023

BUY
$14.75 - $24.62 $110,197 - $183,936
7,471 Added 57.11%
20,552 $365,000
Q2 2023

Aug 14, 2023

BUY
$11.57 - $19.63 $66,365 - $112,597
5,736 Added 78.09%
13,081 $236,000
Q1 2023

May 15, 2023

BUY
$11.92 - $16.27 $5,268 - $7,191
442 Added 6.4%
7,345 $92,000
Q4 2022

Feb 14, 2023

BUY
$14.12 - $18.72 $63,017 - $83,547
4,463 Added 182.91%
6,903 $101,000
Q3 2022

Nov 14, 2022

BUY
$14.08 - $18.5 $12,798 - $16,816
909 Added 59.37%
2,440 $41,000
Q2 2022

Aug 22, 2022

BUY
$11.08 - $19.08 $7,346 - $12,650
663 Added 76.38%
1,531 $22,000
Q1 2022

May 16, 2022

BUY
$14.49 - $24.28 $724 - $1,214
50 Added 6.11%
868 $15,000
Q2 2021

Aug 12, 2021

BUY
$27.16 - $38.59 $4,861 - $6,907
179 Added 28.01%
818 $24,000
Q4 2020

Feb 12, 2021

BUY
$19.17 - $49.62 $12,249 - $31,707
639 New
639 $27,000

Others Institutions Holding TARS

About Tarsus Pharmaceuticals, Inc.


  • Ticker TARS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,658,500
  • Market Cap $1.2B
  • Description
  • Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...
More about TARS
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.